Bionime Corporation

TWSE:4737 Rapporto sulle azioni

Cap. di mercato: NT$4.4b

Bionime Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Bionime.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili23.0%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

None

Ultimo aggiornamenton/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2

Jul 22
Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2

Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year

Jul 01
Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year

These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong

Apr 29
These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong

Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?

Mar 23
Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?

Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?

Mar 05
Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?

Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?

Feb 15
Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?

Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet

Feb 01
Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet

How Has Bionime (TPE:4737) Allocated Its Capital?

Jan 19
How Has Bionime (TPE:4737) Allocated Its Capital?

A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE

Jan 06
A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE

A Look At The Fair Value Of Bionime Corporation (TPE:4737)

Dec 22
A Look At The Fair Value Of Bionime Corporation (TPE:4737)

Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend

Dec 09
Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend

Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment

Nov 24
Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Bionime non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

TWSE:4737 - Stime future degli analisti e dati finanziari passati (TWD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
6/30/20241,858-40-308101N/A
3/31/20241,8097-30595N/A
12/31/20231,7566-238203N/A
9/30/20231,86322-163297N/A
6/30/20232,00243-109284N/A
3/31/20232,1507226393N/A
12/31/20222,21191-171142N/A
9/30/20222,09195-18991N/A
6/30/20222,023115-139129N/A
3/31/20221,86289-20884N/A
12/31/20211,85087-15270N/A
9/30/20211,8791012254N/A
6/30/20211,832111-58205N/A
3/31/20211,77983-62204N/A
12/31/20201,66962-79218N/A
9/30/20201,91373-20270N/A
6/30/20201,95138-4247N/A
3/31/20202,16291248456N/A
12/31/20192,173106267406N/A
9/30/20192,043112117243N/A
6/30/20192,11313255208N/A
3/31/20191,986121-9864N/A
12/31/20182,007128-47122N/A
9/30/20181,9621142164N/A
6/30/20181,84213540166N/A
3/31/20181,821137N/A99N/A
12/31/20171,820150N/A30N/A
9/30/20171,771174N/A134N/A
6/30/20171,780181N/A275N/A
3/31/20171,791192N/A420N/A
12/31/20161,740179N/A458N/A
9/30/20161,654143N/A441N/A
6/30/20161,637119N/A373N/A
3/31/20161,57191N/A228N/A
12/31/20151,61099N/A200N/A
9/30/20151,634101N/A271N/A
6/30/20151,59182N/A305N/A
3/31/20151,57172N/A354N/A
12/31/20141,52554N/A360N/A
9/30/20141,44622N/A272N/A
6/30/20141,45943N/A148N/A
3/31/20141,53672N/A165N/A
12/31/20131,56190N/A129N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if 4737's forecast earnings growth is above the savings rate (1%).

Guadagni vs Mercato: Insufficient data to determine if 4737's earnings are forecast to grow faster than the TW market

Guadagni ad alta crescita: Insufficient data to determine if 4737's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if 4737's revenue is forecast to grow faster than the TW market.

Ricavi ad alta crescita: Insufficient data to determine if 4737's revenue is forecast to grow faster than 20% per year.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if 4737's Return on Equity is forecast to be high in 3 years time


Scoprire le aziende in crescita